    Daniel Teper | IMMUNE PHARMACEUTICALS INC | ZoomInfo.com










 


    Daniel Teper | IMMUNE PHARMACEUTICALS INC | ZoomInfo.com


IMNP Daniel Gedeon Teper Insider Trades for Immune Pharmaceuticals Inc.


































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Immune Pharmaceuticals Inc.

                  NASDAQ: IMNP
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Immune Pharmaceuticals Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 28, 2017, 9:59 p.m.


IMNP

/quotes/zigman/88685368/composite


$
2.27




Change

+0.08
+3.65%

Volume
Volume 122,651
Quotes are delayed by 20 min








/quotes/zigman/88685368/composite
Previous close

$
			2.19
		


$
				2.27
			
Change

+0.08
+3.65%





Day low
Day high
$2.15
$2.27










52 week low
52 week high

            $2.11
        

            $10.20
        


















Insider Activity


Individual




Daniel Gedeon Teper



Dr. Daniel G. Teper is Chief Executive Officer at Wintech Pharmaceuticals. He  is on the Board of Directors at Immune Pharmaceuticals, Inc. Dr. Teper was previously employed as Founder by Novagali Pharma SA, Global President by Euro RSCG Life SA, Senior Vice President & Head-Marketing & Sales by Smithkline Beecham Corp., a Managing Director by Bionest Partners, Partner by Iso Healthcare Consulting, President & Chief Operating Officer by Laboratoires Delagrange, Vice Chairman by Phoenix BioPharm, Inc., and Senior Vice President-Business Development by SoftWatch, Inc. He received his MBA from INSEAD and a doctorate degree from Université Paris-Sud 11.



Transactions


Date
Shares
Transaction
Value





10/06/2016
185,473


 
Derivative/Non-derivative trans. at $0.04 per share.


7,418


08/04/2016
868,902


 
Acquisition at $0.41 per share.


356,249


01/26/2016
42,000


 
Acquisition at $0.59 per share.


24,780


01/19/2016
44,200


 
Acquisition at $0.57 per share.


25,194


01/12/2016
39,400


 
Acquisition at $0.62 per share.


24,428


01/05/2016
62,000


 
Acquisition at $0.81 per share.


50,220


12/07/2015
65,400


 
Acquisition at $0.76 per share.


49,704


10/26/2015
18,400


 
Acquisition at $1.36 per share.


25,024


10/19/2015
18,600


 
Acquisition at $1.34 per share.


24,924


10/12/2015
19,000


 
Acquisition at $1.3 per share.


24,700


10/05/2015
40,700


 
Acquisition at $1.23 per share.


50,061


09/01/2015
7,569


 
Acquisition at $1.29 per share.


9,764


07/08/2015
8,905


 
Derivative/Non-derivative trans. at $1.51 per share.


13,446


08/25/2013
4,260,556


 
Award at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Elliot M. Maza 
Chief Executive Officer & Director




Mr. John  Militello 
Controller, Chief Financial & Accounting Officer




Dr. Daniel Gedeon Teper 
Director




Mr. Daniel  Kazado 
Director




Dr. Jeffrey  Paley 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




8:45 PM EDT
July 28, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
7:48pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
7:39pBarron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News
7:29pA Wild Week in Washington 
6:32pThe dark side of cruises
6:32pThe highest paid athletes in the world, in one chart
6:31pO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
6:31p Trump to Police: 'Don't Be Too Nice'
6:31pHere are 10 co-workers you should avoid like the plague — especially in meetings
6:29pTop 10 most annoying people you may want to unfriend on Facebook 
6:29pThis is one person you should never unfriend on Facebook...
6:29p3 horrible ways typos could alter the course of your life
6:27pPaint your bathroom this color and boost your home’s selling price by $5,400
6:27pAmericans’ new badge of honor: ‘I was blocked by a celebrity!’
6:27p5 weird things I found out about America in my first 24 hours 
6:14pBeyond Tesla: 7 stocks driving the autonomous car revolution
6:14pThese 7 highly taxed companies need Congress to finally act on tax reform
6:11pWatch out: ‘Kids’ are making the most money in this stock market 
6:10p7 real ways for millennials to save money (not by brownbagging and skipping Starbucks)
6:09p‘Game of Thrones’: This computer model predicts who will be killed off — or survive
6:09pThis basic balanced index fund is beating the hedge fund averages
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































Daniel Gedeon Teper - New York, NY | Intelius



























Sign In



We found Daniel Gedeon Teper in New York, NY


Daniel Gedeon Teper

                                                Intelius found that Daniel Gedeon Teper  is  a male from New York, NY.  We have connected them to
                10 addresses,
                9 phones,
                and 4 relatives or associates.
         





Also Known As

Daniel J Teper


Get Report Now

Daniel Has Lived In

New York, NY
Englewood, NJ
Basking Ridge, NJ

Daniel's Relatives

Benjamin Teper
Nicole Teper
Tom Teper
Jonathan Teper







Daniel Gedeon Teper



GenderMale



Professional Status
Chief Executive Officer at 21 West Partners LLC



Get Report Now










Want to know more about Daniel? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Daniel, or use our people search engine to find others.
Get Background Check on Daniel Gedeon Teper
Get a Criminal Check on Daniel Gedeon Teper
Get a Public Record Report on Daniel Gedeon Teper
Get a People Search Report on Daniel Gedeon Teper


Daniel Gedeon Teper's Contact Information
Known Cities Lived In
Find out where Daniel Gedeon Teper has lived as well as Daniel Gedeon Teper's phone numbers and email addresses.




Daniel Gedeon Teper Has Lived in 3 States
New York Address for Daniel Gedeon Teper


1120 o* T** A******* A** 

New York, NY


Has Lived In

New York, NY
Englewood, NJ


Get Full Address Report










Phone Numbers Associated with Daniel Gedeon Teper

(212) ***-**** - New York, NY 
(646) ***-**** - New York, NY 
(914) ***-**** - Tarrytown, NY 


Get Full Phone Report



Email Addresses Associated with Daniel Gedeon Teper

d****l@***.com
d**********r@***.com
d*********e@***.com


Get Email Report




Daniel Gedeon Teper's Education Information
Known Schools Attended
Learn about Daniel Gedeon Teper's academic history.  Find out which schools Daniel Gedeon Teper attended, the dates attended as well as the degrees Daniel Gedeon Teper received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Daniel Gedeon Teper Has Attended 3 Schools
INSEAD 1983 – 1984               Daniel Gedeon Teper has a MBA in Business Administration and Management, General               
Université Paris Sud (Paris Xi)               1978 – 1983               Daniel Gedeon Teper has a Pharmd in Pharmacy               
Université Paris Sud (Paris Xi)               1978 – 1983               Daniel Gedeon Teper has a Pharmd in Pharmacy               


Daniel Gedeon Teper's Professional Information
Information regarding Daniel Gedeon Teper's professional history.  Find out previous places Daniel Gedeon Teper has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Daniel Gedeon Teper Has Worked at 14 Places
Company: 21 West Partners LLC
               Title: Chief Executive Officer
Company: Immune Pharmaceuticals Inc
               Title: Director, Administration
Daniel Gedeon Teper's Experience
Title: Chief Executive Officer
               Company: 21 West Partners LLC
Job Details
               21 West Partners is a global network dedicated to the development and execution of momentum strategies that accelerate and sustain a profitable growth of brands & companies. 21 West acts as advisors and business partners to senior management. Our business practices are best in class and have been implemented across diverse industry sectors. Additionally we have developed 2 industry specific practices in Hospitality & Real Estate and Life Sciences.
Title: Director, Administration
               Company: Immune Pharmaceuticals Inc
Job Details
               Company Size: Less than $1 mil - Employee Range: Less than 25
Additional Professional Information on Daniel Gedeon Teper

 See Daniel Gedeon Teper's LinkedIn Profile



Daniel Gedeon Teper's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Daniel Gedeon Teper


Daniel Gedeon Teper's known Social Networks And Potential Email Matches

Find all of Daniel Gedeon Teper's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Daniel Teper
Username Matches

                  DanielTeper
                  TeperDaniel
                  Daniel.Teper
                  Teper.Daniel
                  Daniel_Teper
                  Teper_Daniel
                  Daniel-Teper
                  Teper-Daniel
                  DTeper
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
D Teper







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.













Daniel Gedeon Teper PharmD,MBA: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 8:45 PM ET
Pharmaceuticals

Company Overview of NEXTherapeutics, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Daniel Gedeon Teper PharmD,MBAChairman and Co-Founder, NEXTherapeutics, Inc.AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 3 different industries.See Board Relationships58--
Background

		Dr. Daniel Gedeon Teper, PharmD, MBA, co-founded Immune Pharmaceuticals, Inc. in 2002 and served as its Chief Executive Officer since August 25, 2013 until April 21, 2017. Dr. Teper co-founded NEXTherapeutics, Inc. He has extensive pharmaceutical management experience and has held senior positions in marketing, new product development and international general management with Novartis, GlaxoSmithKline and Sanofi-Synthelabo. He served as the Managing Director of North ... America BIONEST Partners, Inc., since 2006. He served as a Vice President at ISO Healthcare Consulting, Partner of New York from 2001 to 2003. He served as the Chief Global Officer of GSW Worldwide/ inVentiv Health from 2003 to 2005. He served as the President of Global Operations at EURO RSCG Healthcare Worldwide. Earlier, Dr. Teper founded and served as Chief Executive Officer of Wintec Pharma. He co-founded Novagali, which was acquired by Japan's Santen. He started his career at Sandoz (now Novartis) Global Headquarters in Basel and then in the United States where he had growing responsibilities in sales, marketing and new product development. He held senior executive positions in Europe, first at GSK as Head of Commercial Operations for Glaxo France and then as President and Chief Operating Officer of Laboratoires Delagrange through the acquisition by Synthelabo (now part of Sanofi). He serves as the Chairman of 21 West Partners. He served as the Chairman of Immune Pharmaceuticals, Inc., from August 25, 2013 to December 15, 2014 and serves as its Director. Dr. Teper serves as a Non-executive Director at Phoenix Biopharm Inc since November 2006. He holds a Doctor of Pharmacy degree from Paris XI University and an MBA from INSEAD.Read Full Background




Corporate Headquarters
Riverside Technology CenterCambridge, Massachusetts 02139United StatesPhone: --Fax: --
Board Members Memberships
DirectorImmune Pharmaceuticals, Inc.2006-PresentNon-executive DirectorPhoenix Biopharm Inc
Education
MBA INSEADDoctorate Université Paris-Sud, Paris XI
Other Affiliations
INSEADPhoenix Biopharm IncUniversité Paris-Sud, Paris XIImmune Pharmaceuticals, Inc.


Annual Compensation
				There is no Annual Compensation data available.
				Stocks Options
				There is no Stock Options data available.
				Total Compensation
				There is no Total Compensation data available.
			



Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact NEXTherapeutics, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft



















        Daniel Gédeon Teper (born October 5, 1959), French pharmaceutical executive | Prabook 
    














































Create Biography

You can add biographies of your relatives,  friends, people you admire, as well as your own biography.





        Log in
    


Once logged in, you can add biography in the database




Directories
Newly added



























Edit Profile



General



Education



Career



Works



Life Stance



Personality



Connections



References





People Also Searched For



                    William Jefferson Hague
                  


                    Helge Lund
                  


                    Chris Kirubi
                  


                    Marius Kloppers
                  


                    Tidjane Thiam
                  


                    Carlos Montes
                  








	     Daniel Gédeon  Teper
	     
	  



pharmaceutical executive



		Daniel Gédeon Teper, French pharmaceutical executive. Member pharmaceutical board American Heart Association, Dallas, 1988-1990; president European Institute of Business Administration (Institut Européen d'Administration des Affaires) United States Alumni Association, New York City, 1989-1990, Pharmaceutical Young Managers, Paris, 1982-1983. Member Pharmba.
		
       		



Background




Teper, Daniel Gédeon was born on October 5, 1959 in Paris. Son of Maurice M. and Jeanine (Henry) Teper.
					
					



Education


	 		
			

			Master of Business Administration, European Institute of Business Administration (Institut Européen d'Administration des Affaires), Fontainebleau, France, 1984. Doctor Pharmacy, Paris XI University, Chatenay, France, 1983.
			
       			












Career


	 		
			Product manager Rhone-Poulenc, Paris, 1982-1983. Assistant to vice president marketing Sandoz Ltd., Basel, Switzerland, 1984-1985. Sales representative Sandoz Pharmaceutical Corporation, Tampa, Florida, 1985-1990, business unit manager, marketing director cardiovasculars East Hanover, New Jersey, 1985-1990.Vice president, marketing and sales Glaxo, Paris, 1990-1991. Managing director, chief operation officer Laboratory Delagrange, 1991-1992. Chairman, Chief Executive Officer WINTEC Pharma., 1992-1994.Executive vice president Vacsyn S.A., since 1995.
			
       			












Membership


			Member pharmaceutical board American Heart Association, Dallas, 1988-1990. President European Institute of Business Administration (Institut Européen d'Administration des Affaires) United States Alumni Association, New York City, 1989-1990, Pharmaceutical Young Managers, Paris, 1982-1983. Member Pharmba.
			
    			







Connections


			Married Nicole Cohen-Boularia, November 7, 1982. Children: Benjamin, Jonathan, Tom.
			
    			



father:

					
                            Maurice M. Teper
                        
				







mother:

					
                            Jeanine (Henry) Teper
                        
				







spouse:

					
                            Nicole Cohen-Boularia
                        
				







children:

					
                            Benjamin Teper
                        
				








					
                            Jonathan Teper
                        
				








					
                            Tom Teper
                        
				












Daniel Gédeon Teper



            Back to View page
        
















see more






Add photo











    See on larger map




Born
October 5, 1959

                        (age 57)
                    	
                    	

Paris




Nationality

French




Ethnicity:




French








1984
                                
                            

                                    
                                    European Institute of Business Administration (Institut Européen d'Administration des Affaires)
                                    
                                    
                                        



1983
                                
                            

                                    
                                    Paris XI University
                                    
                                    
                                        



1982 - 1983
                                
                            

                                    Product manager, 
                                    Rhone-Poulenc
                                    
                                        Paris, Kentucky, United States
                                    
                                    
                                        



1984 - 1985
                                
                            

                                    assistant, 
                                    to vice president marketing Sandoz Limited
                                    
                                        Basel, Basel-Stadt, Switzerland
                                    
                                    
                                        



1985 - 1990
                                
                            

                                    
                                    sales representative Sandoz Pharmaceutical Corporation
                                    
                                        Tampa, Florida, United States
                                    
                                    
                                        



1990 - 1991
                                
                            

                                    vice president
                                    
                                    
                                        Paris, Kentucky, United States
                                    
                                    
                                        



1991 - 1992
                                
                            

                                    managing director, 
                                    Laboratory Delagrange
                                    
                                        




1991 - 1992
                                
                            

                                    chief operation officer, 
                                    Laboratory Delagrange
                                    
                                        




1992 - 1994
                                
                            

                                    chairman, 
                                    WINTEC Pharma.
                                    
                                        




1992 - 1994
                                
                            

                                    Chief Executive Officer, 
                                    WINTEC Pharma.
                                    
                                        




1995
                                
                            

                                    executive, 
                                    vice president Vacsyn Societe Anonyme
                                    
                                        




show more ...







			Go
			
			up
		  
Edit Profile


















Daniel Gedeon Teper - Immune Pharmaceuticals Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsDaniel Gedeon TeperImmune Pharmaceuticals (IMNP)CEO, Director, Ten Percent OwnerRanked #32,160 out of 33,852 Insiders on TipRanksDaniel Gedeon Teper's PerformanceProfitable Transactions0 out of 5 profitable transactionsAverage  Return-68.0%Average return per transactionEach transaction is measured over a 1 Year3 Months1 Month period, and compared to No BenchmarkS&P 500Sector.How are Insiders Ranked? Insider Holdings 100.0% Immune Pharmaceuticals (IMNP)$3MSee the Top Stocks by Insiders > Insider RolesImmune Pharmaceuticals (IMNP): CEO, Director, Ten Percent OwnerSee the Top 25 Corporate Insiders > Most Profitable Insider TradeStock: Immune Pharmaceuticals (IMNP)Transaction Type: Informative BuyDates: Oct 11, 2016 - TodayGain: -53.0%See the Latest Stocks Traded by Insiders > Daniel Gedeon Teper's Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DateIMNPImmune PharmaceuticalsCEO, Director, Ten Percent Owner$3,329,643Informative Buy$7,418.92Oct 11, 2016Success Rate on Stock0 out of 5 profitable transactions on IMNPAverage Profit on StockAverage return per transaction on IMNP -68.0% Track Record Showing:All TransactionsInformative TransactionsDateTransactionAmountNo. of SharesPrice per ShareProfitForm 4 Oct 11, 2016 Informative Buy $7K 185,473 $5 -53.00%  Aug 04, 2016 Informative Buy $356K 937,500 $6.6 -64.30%  Jan 26, 2016 Uninformative Buy $25K 42,000 $11 N/A Show MoreSee All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by





























Daniel Gedeon Teper - Chief Executive Officer at Cytovia, Inc.



























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology








            You have  
            
9 free profiles

              left this month   
			      

                Start Your Free Trial ➤
              








            Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there?
            

                View on RelSci Pro ➤
              




























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink





Daniel Gedeon Teper
Chief Executive Officer at Cytovia, Inc.



Overview
In The News Relationships Paths
Education Career History Boards & Committees Public Holdings Transactions 


Daniel Gedeon Teper
Chief Executive Officer at Cytovia, Inc.



 Overview



Age



57
                                  (Born 1960)
                                              




Notable Companies


Havas Life Paris SA

Laboratoires Delagrange

Cytovia, Inc.




Board Seats



3





Number of Relationships



                This person is connected to 3,164 people.
              






 In The News
          See more




Business Wire
July 13, 2017





                        IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting the Use of Ceplene® in Acute Myeloid Leukemia (AML) and Other Hematological Cancers with MutatedNPM1                    





Business Wire
July 11, 2017





                        Cytovia Inc, Immune Pharmaceuticals' Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene® in Latin America                    





PR Newswire
July 5, 2017





                        IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of Ceplene® in Combination with Low-Dose IL-2 in Patients With Acute Myeloid Leukemia, Recently Published in Leukemia, a Leading Hematology Journal                    





PR Newswire
June 29, 2017





                        Immune Pharmaceuticals' Oncology Subsidiary, Cytovia Inc. Provides Update to Proposed Pint Pharma Transaction: Substantial Agreement Reached on Material Terms of the Licensing and Commercialization of Ceplene® in Latin America                    





PR Newswire
June 20, 2017





                        Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML)                    







See full news coverage and complete stories with RelSci Professional.

Create Your News Feed








See  More 






 Relationships
              See Details




Elliot Maza

Chief Executive Officer & Director at IMMUNE PHARMACEUTICALS INC




Robert W. Cook

Chief Financial Officer at CorMedix, Inc.





Gad Berdugo

Former Chief Financial Officer, Secretary & Executive Vice President-Administration at IMMUNE PHARMACEUTICALS INC




Cameron Durrant

Chairman & Chief Executive Officer at KaloBios Pharmaceuticals, Inc.





Ranch C. Kimball

Chief Operating Officer at Babson College




Rene Lerer

President at Florida Blue





David Sidransky

Director, Head & Neck Cancer Research Division at The Johns Hopkins University




Ana I. Stancic

Former Chief Executive Officer, Chief Operating Officer, Chief Financial Officer & Executive Vice President at Enzon Pharmaceuticals Inc.





John Neczesny

Managing Director at Oberon Securities LLC




Isaac Kobrin

Former Chief Medical Officer at Actelion Ltd.







See 3,154 more listings with RelSci Professional.

Start My Free Trial ➤








See 3,154 More 


 


 Paths to Daniel Gedeon Teper



            Daniel Gedeon Teper          




 You



 Connections via Relationship Science



 Daniel Gedeon Teper






Sync your contacts to see how you can connect with Daniel Gedeon Teper.

Start My Free Trial ➤








See  More 


 


 Educational Background



MBA 


INSEAD

                  INSEAD is a graduate business school with campuses in Europe, Asia and the Middle East. 
INSEAD, widely considered one of the best business schools in the world, allows its students to study in the US (West Coast- San Francisco via Wharton exchange, East Coast- Philadelphia via Wharton exchange, Midwest- Evanston near Chicago via Kellogg exchange), in Asia (Singapore via INSEAD Asia Campus exchange and Shanghai via CEIBS exchange), in the Middle East (Abu Dhabi via INSEAD Middle East Campus exchange) and in Europe (Fontainebleau via INSEAD Europe Campus exchange)                




Doctor of Pharmacy 


Université Paris-Sud 11

                  University of Paris-Sud is a school in Orsay.                





 Career History



Chief Executive Officer

                                    Current                


Cytovia, Inc.


                  Cytovia, Inc. provides biomedical research services. The firm discovers and develops therapeutics and products to assist physicians in curing cancer and certain degenerative diseases. The company is headquartered in San Diego, CA.                




Chief Executive Officer

                                    Current                


Wintech Pharmaceuticals






President & Chief Operating Officer of Laboratoires Delagrange

                                    Tenure Unconfirmed                


Sanofi


                  Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health                




Senior Vice President-Business Development

                                    Prior - 2010                


SoftWatch, Inc.


                  SoftWatch, Inc. provides Internet relationship management solutions and services. The company's product, SoftWatch relationship server enables companies to build and deploy healthcare portals and communities for collecting market data. It offers services to the health and pharmaceutical industries. SoftWatch was founded in 1994 and is headquartered in Pawling, NY.                




Founder

                                    1999 - Prior                


Novagali Pharma SA


                  Novagali Pharma SA specializes in research, development and marketing of ophthalmic drugs. Their product pipeline includes products at various stages of development, which address diseases encountered at the three different segment levels of the eye which are surface, anterior and posterior segments. Some of these diseases are dry eye, allergy, glaucoma and retinopathies. Their formulations are based on their technology platforms Novasorb and Eyeject, which optimize bioavailability of drugs as well as safety and comfort for the patient. The company was founded on August 8, 2000 and is headquartered in Evry, France.                




Global President

                                    1996 - 1999                


Havas Life Paris SA


                  Havas Life Paris SA, a subsidiary of Havas SA, is a company headquartered in Paris, France, that provides advertising and marketing services.                




Founder

                                    1993 - 2017                


IMMUNE PHARMACEUTICALS INC


                  Immune Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It engages in the development and commercialization of targeted therapeutics, including mAbs nanotherapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer. The company acquires, develops and commercialises prescription drug products. Immune Pharmaceuticals was founded by Daniel G. Teper and Jean Elie Kadouche in March, 1993 and is headquartered in New York, NY.                




Senior Vice President & Head-Marketing & Sales

                                    1990 - 1992                


GlaxoSmithKline LLC


                  Smithkline Beecham Corp. engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products for customers in the United States. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. The company also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.                




Chief Executive Officer & Director

                                    Prior                


EpiCept Corp.


                  EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY.                




Chief Executive Officer

                                    Prior                


Immune Pharmaceuticals Ltd.


                  Part of Immune Pharmaceuticals, Inc., Immune Pharmaceuticals Ltd. is an Israeli company located in Herzliya-Pituach that develops pharmaceutical products for the treatment of cancer and pain. On 26 Aug 13 EpiCept Corp. acquired Immune Pharmaceuticals Ltd. for $21.43 million.                




President & Chief Operating Officer

                                    Prior                


Laboratoires Delagrange






Partner, ISO Healthcare Consulting

                                    Prior                


Deloitte LLP


                  Deloitte LLP provides audit, consulting, financial advisory, risk management, tax, and related services. It offers financial transaction, regulatory, forensic and compliance, resilience and merger and acquisition services. The company was founded on March 7, 1995 and is headquartered in New York, NY.                




Partner

                                    Prior                


Iso Healthcare Consulting






Managing Director

                                    Prior                


Bionest Partners, Inc.


                  Bionest Partners, Inc. provides consulting services to the medical industry. The firm offers expertise in all aspects of the life sciences including medical devices, diagnostics, research and development, marketing, corporate development, and personal medicine strategy. The company was founded by Robert J. Easton in 2003 and is headquartered in New York, NY.                




Professional

                                    Prior                


Novartis AG


                  Novartis AG develops, manufactures, and markets healthcare products. It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, and Corporate Activities. The Pharmaceuticals segment provides patent-protected prescription medicines. The Alcon segment offers surgical, ophthalmic pharmaceuticals, and vision care products. The Sandoz segment supplies generic pharmaceuticals. The Corporate Activities segment includes other items of income and expense which are not attributable to specific segments such as certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations, and sponsorships. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.                




President, Global Euro RSCG Healthcare Worldwide

                                    Prior                


Havas Worldwide LLC


                  Havas Worldwide LLC provides advertising and marketing services, healthcare and corporate communications. It also offers campaign management, branding and marketing and public relations services. The company was founded in 1991 and is headquartered in New York.                





 Boards & Committees



Corporate Boards ▾




Member, Board of Directors

                    1993 - Current                  


IMMUNE PHARMACEUTICALS INC

                    Immune Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It engages in the development and commercialization of targeted therapeutics, including mAbs nanotherapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer. The company acquires, develops and commercialises prescription drug products. Immune Pharmaceuticals was founded by Daniel G. Teper and Jean Elie Kadouche in March, 1993 and is headquartered in New York, NY.                  




Chairman of the Board & Chief Executive Officer

                    2013 - Prior                  


EpiCept Corp.

                    EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY.                  




Vice Chairman

                    Prior                  


Phoenix BioPharm, Inc.

                    Phoenix BioPharm Inc. operates as pharmaceutical company, established to bring to market reprofiled therapeutics with a focus on the treatment of cardiovascular and central nervous system disease segments and targeted specialty products. The company was founded in 2003 and is headquartered in Palm Beach Gardens, FL.                  





 Public Holdings






Restricted data only for RelSci Professional users.

Start My Free Trial ➤








See  More 


 


 Transactions



 Details Hidden



                  IMMUNE PHARMACEUTICALS INC raised money in a private placement transaction                                  




 Details Hidden



                  EpiCept Corp. purchases Immune Pharmaceuticals Ltd.   resulting in a new company IMMUNE PHARMACEUTICALS INC                                  





 Other Affiliations




              Daniel Gedeon Teper is affiliated with
                            Cytovia, Inc., Wintech Pharmaceuticals, Sanofi, SoftWatch, Inc., Novagali Pharma SA, Havas Life Paris SA, IMMUNE PHARMACEUTICALS INC, GlaxoSmithKline LLC, EpiCept Corp., Immune Pharmaceuticals Ltd., Laboratoires Delagrange, Deloitte LLP, Iso Healthcare Consulting, Bionest Partners, Inc., Novartis AG, Havas Worldwide LLC, IMMUNE PHARMACEUTICALS INC, EpiCept Corp., Phoenix BioPharm, Inc..
            





You've reached your 10 free profiles limit this month.
Upgrade to RelSci Pro today to enjoy unlimited article views and much more!

Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.












Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤













